DSIP (Emideltide)
No Legal PathwaySleep Peptide
Based on public FDA records, we don't see an approval or a shortage-list listing — both are usually preconditions for a 503A/503B exception. From what's publicly available, we don't find a compounding route under any formulation theory, but this is our reading of public sources, not legal advice.
Not legal advice. Every status on this page is our own reading of public FDA guidance, shortage listings, and committee materials — it has not been reviewed by an attorney and is not a legal determination. "Contested" means pharmacies and regulators publicly disagree, not that we're resolving the disagreement. Verify independently, and check with counsel, before relying on any entry here.
Current status
Marketed as a sleep-promoting peptide. FDA's Pharmacy Compounding Advisory Committee considered it — under the name Emideltide — for addition to the 503A bulk substances list at the same July 23–24, 2026 meeting covering BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax, and voted 6–7 against recommending it, the only one of the seven reviewed substances the committee declined to back. Never FDA-approved and no shortage-list history, so no compounding pathway currently exists.
Last changed: 2026-07-24